Novel use of regulatory t cell-specific surface protein lrig-1
AssigneeGood T Cells, Inc.
InventorSang-Kyou LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.
Claims4
A method for treating cancer, comprising administering an effective amount of siRNA complementary to a nucleotide encoding Lrig1 protein expressed in regulatory T cells.
Dependencies are inferred from the claim text.